Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor
(ER)–positive primary breast cancer triaged to chemotherapy when the protein encoded by …

Background Preoperative and perioperative aromatase inhibitor (POAI) therapy has the
potential to improve outcomes in women with operable oestrogen receptor-positive primary …

Purpose To investigate the relationships between biomarker changes in breast cancer
during neoadjuvant (preoperative) endocrine therapy. Patients and Methods The IMPACT …

Background Studies have shown that Ki-67 response after short-term neoadjuvant
aromatase inhibitors may predict recurrence in postmenopausal breast cancer, whereas its …

Background Ki67 has been identified as a prognostic and predictive marker for breast
cancer and it was suggested that it may contribute to pathologic complete response (pCR) …

Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological
complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive …

The study of changes in proliferation as a marker of treatment benefit during presurgical
endocrine treatment of breast cancer has become increasingly popular, particularly using …

Background Understanding how tumor response is related to relapse risk would help
clinicians make decisions about additional treatment options for patients who have received …

Abstract Purpose: The value of Ki67 measured on residual disease after neoadjuvant
chemotherapy is not sufficiently described. Experimental Design: Participants of the …

Purpose To compare the prognostic significance of proliferation, as assessed by Ki67
expression, in breast cancer before and after neoadjuvant chemotherapy. Methods A …